MARKET

SYNH

SYNH

SYNEOS HEALTH
NASDAQ

Real-time Quotes | Nasdaq Last Sale

82.64
-0.18
-0.22%
After Hours: 82.64 0 0.00% 17:33 05/10 EDT
OPEN
83.06
PREV CLOSE
82.82
HIGH
84.01
LOW
82.34
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
89.95
52 WEEK LOW
50.27
MARKET CAP
8.62B
P/E (TTM)
44.03
1D
5D
1M
3M
1Y
5Y
Insider Trends: 90-Day Insider Selling Trend Prolonged at Syneos Health
MT Newswires · 4h ago
Foghorn Therapeutic, Syneos Health Post Clinical Trial Titled 'FHD-286 in Subjects With Metastatic Uveal Melanoma' To ClinicalTrials.Gov
https://clinicaltrials.gov/ct2/show/NCT04879017
Benzinga · 12h ago
Syneos Health Leaders Recognized For Visionary Healthcare Expertise Through HBA
Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Lynn Hamilton, Senior Director, Clinical Operations and Clinical Development Services, and Katya Magonova, MBA, Senior Engagement Manager,...
GlobeNewswire · 4d ago
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3)
Benzinga · 6d ago
BRIEF-Syneos Health Announces Pricing Of Secondary Offering Of Common Stock
reuters.com · 05/04 01:39
Syneos Health commences 7M share secondary offering
Syneos Health (SYNH) has commenced an underwritten secondary offering of 7M shares.Selling stockholders intend to grant the underwriter a 30-day option to purchase up to 1.05M additional shares.Syneos Health is
Seekingalpha · 05/03 20:43
Syneos Health Announces Secondary Offering of Common Stock
MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced it commenced an underwritten secondary offering b...
GlobeNewswire · 05/03 20:40
Syneos Health Launches "Lab to Life" Enterprise Partnership with Komodo Health
MORRISVILLE, May 03, 2021 (GLOBE NEWSWIRE via COMTEX) -- MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health(R) (Nasdaq:SYNH), the only fully...
GlobeNewswire · 05/03 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYNH. Analyze the recent business situations of SYNEOS HEALTH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYNH stock price target is 94.55 with a high estimate of 106.00 and a low estimate of 83.00.
EPS
Institutional Holdings
Institutions: 441
Institutional Holdings: 135.48M
% Owned: 129.90%
Shares Outstanding: 104.29M
TypeInstitutionsShares
Increased
143
9.70M
New
56
4.56M
Decreased
80
10.69M
Sold Out
39
2.07M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Independent Director
John Dineen
Chief Executive Officer/Director
Alistair Macdonald
Chief Financial Officer
Jason Meggs
Corporate Executive
Paul Colvin
Corporate Executive
Michelle Keefe
Chief Human Resource Officer
Lisa van Capelle
Chief Human Resource Officer
Lisa Van Capelle
Director
Tom Allen
Senior Vice President - Finance/Chief Accounting Officer
Donna Kralowetz
General Counsel/Secretary
Jonathan Olefson
Independent Director
Todd Abbrecht
Independent Director
Thomas Allen
Independent Director
Bernadette Connaughton
Independent Director
Linda Harty
Independent Director
William Klitgaard
Independent Director
John Maldonado
Independent Director
Kenneth Meyers
Independent Director
Matthew Monaghan
Independent Director
Joshua Nelson
No Data
About SYNH
Syneos Health Inc. is a fully integrated biopharmaceutical solutions providing company. The Company offers both stand-alone and integrated biopharmaceutical product development solutions through its Contract Research Organization (CRO) and Contract Commercial Organization (CCO), ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. It brings together approximately 24,000 clinical and commercial professionals with the ability to support customers in more than 110 countries. Together it shares insights, leverages latest technologies and apply advanced business practices to deliver important therapies to patients.

Webull offers kinds of Syneos Health Inc stock information, including NASDAQ:SYNH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYNH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYNH stock methods without spending real money on the virtual paper trading platform.